Shionogi Inks $150M Deal for Global Rights to Oral Pompe Disease Therapy MZE001; GSK Appoints New China General Manager
GSK
Pharmaceutical R&D Manufacturer
GSK China Has Been Active Recently.
According to media reports, Riccardo Colella, Senior Vice President of GSK Greater China and Intercontinental Region, recently announced important personnel changes to employees:
Qi Xin, currently Vice President of GSK and General Manager of China, has been promoted to Vice President of GSK's Greater China and Intercontinental Region, while also serving as the head of the vaccine business.
Yu Huiming, currently Vice President of GSK and General Manager of Taiwan, will succeed Qi Xin as Vice President of GSK and General Manager of China.
Japanese pharmaceutical companies are making strong moves to introduce new products.
On May 10, Shionogi & Co., Ltd. announced an exclusive licensing agreement with Maze Therapeutics to obtain global exclusive rights to the latter's orally administered Pompe disease therapy, MZE001. Under the agreement, Shionogi will pay an upfront fee of $150 million, while Maze is eligible to receive milestone payments based on development, regulatory, and commercial achievements.
In the past day, what hot topics in the pharmaceutical market at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Vazyme and Sinopharm Cardinal Health Sign Cooperation Agreement
On May 10, Vazyme announced that it had recently signed a "Cooperation Agreement" with Sinopharm Cardinal Health (Shanghai) Medical Co., Ltd. regarding the business cooperation of the company's Alzheimer's disease (AD) blood test products.
2) GSK China Leadership Change
Recently, according to media reports, Corinna Cortes, Senior Vice President of GSK Greater China and Intercontinental Region, has announced to employees that Qi Xin, current Vice President of GSK and General Manager of China, has been appointed as Vice President of GSK Greater China and Intercontinental Region and Head of Vaccines Business; Yu Hui-ming, current Vice President of GSK and General Manager of Taiwan region, will take over as Vice President of GSK and General Manager of China.
/ 02 /
Pharmaceuticals and Medical Devices Updates
1) HuiBaoyuan Biotech's JP001 Tablets Approved for Clinical Trials
On May 10, according to the CDE official website, Hui Baoyuan Biotechnology's JP001 tablet has been approved for clinical trials, aiming to conduct research on treating newly diagnosed glioblastoma.
2) SSS39 Injection from 3SBio Approved for Clinical Trials
On May 10, according to the CDE official website, SSS39 Injection from 3SBio was approved for clinical trials, intended for reducing the immunogenicity of biological therapies.
3) SPH7485 Tablet from Shanghai Pharmaceutical Group Approved for Clinical Trials
On May 10, according to the CDE official website, SPH7485 tablets developed by Shanghai Pharmaceutical Group were approved for clinical trials, intended for the treatment of advanced solid tumors.
4) Thermopharm's BIOS2207 Approved for Clinical Trials
On May 10, according to the CDE official website, Sino Pharm's BIOS2207 has been approved for clinical trials, intended for the treatment of partial-onset seizures in adults and children aged 4 years and above (with or without secondary generalization).
5) GBI268 Injection from Zhiyao Bio Approved for Clinical Trials
On May 10, according to the CDE official website, Zhiyao Bio's GBI268 Injection has been approved for clinical trials and is proposed to conduct research on postoperative local analgesia.
6) AstraZeneca's MEDI5752 Approved for Clinical Trials
On May 10, according to the CDE official website, AstraZeneca's MEDI5752 was approved for clinical trials, intended to carry out research on the treatment of solid tumors.
7) Surex Bio obtained the medical device registration certificate for the Dengue Virus NS1 Antigen Detection Kit.
On May 10, Shuoshi Biotechnology announced that the Dengue Virus NS1 Antigen Test Kit (Colloidal Gold Method) has been approved for marketing. This kit is used for the qualitative detection of Dengue Virus NS1 antigen in human serum or plasma samples.
8) HeartFlow Medical's ALTAVALVE Granted FDA Breakthrough Device Designation
On May 9, HeartFlow Medical announced that its transcatheter mitral valve replacement medical device, ALTAVALVE, had been granted Breakthrough Device Designation by the FDA.
9) MicroPort Robot's Toumai Endoscopic Surgical Robot Obtains EU CE Certification
On May 9, MicroPort Robot announced that the Tumai laparoscopic surgical robot had obtained EU CE certification.
/ 03 /
Overseas Pharma News
1) Shionogi introduces oral Pompe disease therapy
On May 10, Shionogi announced an exclusive licensing agreement with Maze Therapeutics to obtain the global exclusive rights to the latter's orally-administered Pompe disease therapy, MZE001. Shionogi will pay $150 million upfront, and Maze will be eligible for milestone payments based on development, regulatory, and commercial achievements.
2) Novavax Announces Collaboration Agreement with Sanofi
On May 10, Novavax announced a collaboration agreement with Sanofi. According to the agreement, the two companies will jointly commercialize Novavax's COVID-19 vaccine starting next year and co-develop a combination vaccine targeting coronaviruses and influenza. Under the collaboration, Sanofi will leverage Novavax’s COVID-19 vaccine and its flagship Matrix-M adjuvant technology to develop new vaccine products. As part of the deal, Sanofi will pay Novavax an upfront payment of $500 million and up to $700 million in additional payments upon achieving development, regulatory, and commercial milestones. The total value of this deal is approximately twice Novavax's current market capitalization.
Text by Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.
